Breaking News Instant updates and real-time market news.

PFE

Pfizer

$42.32

0.51 (1.22%)

06:47
03/20/19
03/20
06:47
03/20/19
06:47

Pfizer secures exclusive option to acquire Vivet Therapeutics

Vivet Therapeutics and Pfizer announced that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer and Vivet will collaborate on the development of VTX-801, Vivet's proprietary treatment for Wilson disease. Under the terms of the transaction, Pfizer paid approximately $51M upon signing and may pay up to $635.8M inclusive of the option exercise payment and subject to certain clinical, regulatory, and commercial milestones. Pfizer can exercise its option to acquire 100% of Vivet following the company's delivery of certain data from the Phase I/II clinical trial for VTX-801. As part of the transaction, Pfizer senior executive Monika Vnuk, M.D., Vice President, Worldwide Business Development, will join Vivet's Board of Directors. Other terms of the transaction were not disclosed.

  • 20

    Mar

  • 30

    Apr

  • 18

    May

PFE Pfizer
$42.32

0.51 (1.22%)

01/31/19
01/31/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Outperform from Neutral at Credit Suisse and to Buy from Hold at Argus. 2. Tiffany (TIF) upgraded to Overweight from Neutral at Atlantic Equities with analyst Daniela Nedialkova saying the pullback has been largely driven by macro concerns while fundamentals of the brand are strong and preliminary FY19 guidance is conservative. 3. Scotts Miracle-Gro (SMG) upgraded to Neutral from Underweight at JPMorgan with analyst Jeffrey Zekauskas citing valuation. 4. Geron (GERN) upgraded to Buy from Neutral at B. Riley FBR with analyst George Zavoico saying he believes investors should focus on the pivotal Phase III trial of imetelstat. 5. Ralph Lauren (RL) upgraded to Outperform from Market Perform at Telsey Advisory with analyst Dana Telsey saying the company's improving sakes, combined with ongoing margin expansion, should bolster its earnings. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/20/19
SBSH
02/20/19
UPGRADE
Target $41
SBSH
Neutral
Pfizer resumed with a Neutral from Sell at Citi
Citi analyst Andrew Baum resumed coverage of Pfizer following a period of restriction and upgraded the shares to Neutral from Sell. He also boosted his price target for the shares to $41 from $37. The analyst says the recent pullback in the stock, along with the 5%-8% 2019-2021 consensus estimate reductions, gives him the opportunity to close his Sell rating. He believes management action on business development, cost saving or moves to better monetize Pfizer's Established Product business are likely near-term drivers of the stock.
02/20/19
02/20/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) resumed with a Neutral from Sell at Citi with analyst Andrew Baum saying the recent pullback in the stock, along with the 5%-8% 2019-2021 consensus estimate reductions, gives him the opportunity to close his Sell rating. 2. Transocean (RIG) and Diamond Offshore (DO) were upgraded to Overweight from Underweight at Barclays. 3. American Axle (AXL) upgraded to Buy from Neutral at BofA/Merrill with analyst John Murphy citing progress with restructuring, GM's (GM) truck cycle, and balance sheet deleveraging. 4. Credit Suisse (CS) upgraded to Hold from Sell at Berenberg. 5. Ipsen (IPSEY) upgraded to Neutral from Sell at Goldman Sachs with analyst Diana Na citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/26/19
LEHM
02/26/19
NO CHANGE
LEHM
Galapagos weakness could be tied to Pfizer safety alert, says Barclays
Barclays believes the weakness today in Galapagos NV (GLPG) could be attributed to, at least in part, the FDA's safety communication on Pfizer's (PFE) post-marketing study of 10mg daily Xeljanz. Competitor safety issues with higher dose JAK inhibitors was a major focus of Galapagos' post-earnings conference call last week, Barclays tells investors in a research note. Galapagos management, while limited in what it can say pending the data, seems to believe they can get both doses approved, Barclays contends. Further, the firm points out that the company has received no communication and sees no reason to conclude that the FDA has determined that thromboembolic events are a class effect of the JAKs. Shares of Galapagos are down 1.5%, or $1.45, to $97.28 in late morning trading.

TODAY'S FREE FLY STORIES

LRCX

Lam Research

$271.29

-1.38 (-0.51%)

05:52
11/12/19
11/12
05:52
11/12/19
05:52
Recommendations
Lam Research analyst commentary  »

Lam Research price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

ASUR

Asure Software

$9.20

0.01 (0.11%)

05:50
11/12/19
11/12
05:50
11/12/19
05:50
Recommendations
Asure Software analyst commentary  »

Asure Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

MTEM

Molecular Templates

$9.20

0.04 (0.44%)

05:49
11/12/19
11/12
05:49
11/12/19
05:49
Conference/Events
Molecular Templates to host analyst & investor meeting »

Analyst & Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

CRDNF

Cardinal Resources

$0.00

(0.00%)

05:47
11/12/19
11/12
05:47
11/12/19
05:47
Initiation
Cardinal Resources initiated  »

Cardinal Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

05:45
11/12/19
11/12
05:45
11/12/19
05:45
General news
NFIB Small Business Optimism Index level to be reported at 06:00 »

October NFIB Small…

ALB

Albemarle

$67.72

-0.29 (-0.43%)

05:37
11/12/19
11/12
05:37
11/12/19
05:37
Downgrade
Albemarle rating change  »

Albemarle downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 12

    Dec

CBMG

Cellular Biomedicine

$17.86

0.11 (0.62%)

05:36
11/12/19
11/12
05:36
11/12/19
05:36
Downgrade
Cellular Biomedicine rating change  »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNIRF

Senior plc

$0.00

(0.00%)

05:36
11/12/19
11/12
05:36
11/12/19
05:36
Downgrade
Senior plc rating change  »

Senior plc downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SOLVY

Solvay

$0.00

(0.00%)

05:34
11/12/19
11/12
05:34
11/12/19
05:34
Upgrade
Solvay rating change  »

Solvay upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

BOX

Box

$16.45

-0.495 (-2.92%)

05:32
11/12/19
11/12
05:32
11/12/19
05:32
Downgrade
Box rating change  »

Box downgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

CTVA

Corteva

$26.74

0.54 (2.06%)

05:30
11/12/19
11/12
05:30
11/12/19
05:30
Initiation
Corteva initiated  »

Corteva initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

IFJPY

Informa

$0.00

(0.00%)

05:30
11/12/19
11/12
05:30
11/12/19
05:30
Upgrade
Informa rating change  »

Informa upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPKFF

LPKF Laser & Electronics

$0.00

(0.00%)

05:29
11/12/19
11/12
05:29
11/12/19
05:29
Downgrade
LPKF Laser & Electronics rating change  »

LPKF Laser &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETN

Eaton

$91.87

-0.35 (-0.38%)

05:28
11/12/19
11/12
05:28
11/12/19
05:28
Downgrade
Eaton rating change  »

Eaton downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 19

    Nov

  • 19

    Nov

COVTY

Covestro

$0.00

(0.00%)

05:27
11/12/19
11/12
05:27
11/12/19
05:27
Downgrade
Covestro rating change  »

Covestro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPRUY

Kering

$0.00

(0.00%)

05:27
11/12/19
11/12
05:27
11/12/19
05:27
Upgrade
Kering rating change  »

Kering upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$16.11

-0.1 (-0.62%)

05:26
11/12/19
11/12
05:26
11/12/19
05:26
Upgrade
Fiat Chrysler rating change  »

Fiat Chrysler upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PUGOY

Peugeot

$0.00

(0.00%)

05:26
11/12/19
11/12
05:26
11/12/19
05:26
Upgrade
Peugeot rating change  »

Peugeot upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAVS

Ageagle Aerial Systems

$0.42

0.0385 (10.13%)

05:25
11/12/19
11/12
05:25
11/12/19
05:25
Conference/Events
Ageagle Aerial Systems to host business news update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

NNGRY

NN Group

$0.00

(0.00%)

05:25
11/12/19
11/12
05:25
11/12/19
05:25
Downgrade
NN Group rating change  »

NN Group downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$17.10

-0.22 (-1.27%)

05:23
11/12/19
11/12
05:23
11/12/19
05:23
Earnings
Embraer backs FY20 revenue view of $2.5B-$2.8B »

May not compare to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

PRBZF

Premium Brands

$0.00

(0.00%)

05:22
11/12/19
11/12
05:22
11/12/19
05:22
Downgrade
Premium Brands rating change  »

Premium Brands downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$17.10

-0.22 (-1.27%)

05:21
11/12/19
11/12
05:21
11/12/19
05:21
Earnings
Embraer backs FY19 revenue guidance of $5.3M-$5.7M, consensus $5.37M »

Embraer reaffirms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

OZMLF

Oz Minerals

$0.00

(0.00%)

05:21
11/12/19
11/12
05:21
11/12/19
05:21
Downgrade
Oz Minerals rating change  »

Oz Minerals downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SESN

Sesen Bio

$1.14

(0.00%)

05:20
11/12/19
11/12
05:20
11/12/19
05:20
Conference/Events
Sesen Bio to host business news update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.